Haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen
Accession Number
DB10342
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Other vaccines
Description

Haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen is a vaccine containing outer membrane antigen extracted from Haemophilus influenzae.

Synonyms
  • Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PedvaxHIBInjection, suspension7.5 ug/0.5mLIntramuscularMerck Sharp & Dohme Corp.1989-12-20Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
ComvaxHaemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen (7.5 ug/0.5mL) + Hepatitis B virus subtype ADW HBSAG surface protein antigen (5 ug/0.5mL)Injection, suspensionIntramuscularMerck Sharp & Dohme Limited1996-10-022016-08-19Us
VaxelisHaemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen (3 ug/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (20 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (20 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (15 [Lf]/0.5mL) + Hepatitis B virus subtype ADW HBSAG surface protein antigen (10 ug/0.5mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (29 [D'ag'U]/0.5mL) + Poliovirus type 2 antigen (formaldehyde inactivated) (7 [D'ag'U]/0.5mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (26 [D'ag'U]/0.5mL)Injection, suspensionIntramuscularMCM Vaccine Co.2018-12-21Not applicableUs
Categories
UNII
LUY6P8763W
CAS number
Not Available

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2-MethoxyethanolThe therapeutic efficacy of Haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with 2-Methoxyethanol.
25-desacetylrifapentineThe therapeutic efficacy of Haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with 25-desacetylrifapentine.
6-Deoxyerythronolide BThe therapeutic efficacy of Haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with 6-Deoxyerythronolide B.
9-(N-methyl-L-isoleucine)-cyclosporin AThe therapeutic efficacy of Haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe therapeutic efficacy of Haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Abatacept.
AbetimusThe therapeutic efficacy of Haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Abetimus.
Acetic acidThe therapeutic efficacy of Haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Acetic acid.
Acetyl sulfisoxazoleThe therapeutic efficacy of Haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Acetyl sulfisoxazole.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen is combined with Acetylsalicylic acid.
ActeosideThe therapeutic efficacy of Haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Acteoside.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910521

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedPreventionHaemophilus Influenzae Type B / Neisseria Meningitidis1
2CompletedPreventionStreptococcal Infections1
3CompletedPreventionBacterial Infections / Neisseria Meningitidis / Virus Diseases2
3CompletedPreventionBacterial Infections / Virus Diseases2
3CompletedPreventionHaemophilus Influenza b Infections / Haemophilus Influenzae Type B / Meningococcal Infections / Neisseria Meningitidis / Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine1
3CompletedPreventionHaemophilus Influenzae Type B / Haemophilus Influenzae Type B Infection / Meningococcal Infections / Neisseria Meningitidis1
3CompletedPreventionHaemophilus Influenzae Type B / Neisseria Meningitidis1
3CompletedPreventionHaemophilus Influenzae Type B / Viral Hepatitis B1
3CompletedPreventionMumps / Rubella / Rubeola / Varicella1
4CompletedPreventionHepatitis A Virus1
Not AvailableActive Not RecruitingNot AvailableDiphtheria / Haemophilus Infections / Pertussis / Poliomyelitis / Tetanus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, suspensionIntramuscular
Injection, suspensionIntramuscular7.5 ug/0.5mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:03 / Updated on June 04, 2019 07:13